https://www.selleckchem.com/pr....oducts/irak-1-4-inhi
This study evaluates in-hospital, 30-day, and 1-year outcomes post-transcatheter aortic valve replacement (TAVR) in end stage liver disease (ESLD) and/or end stage renal disease (ESRD) compared with patients without these comorbidities. TAVR is an alternative to surgical aortic valve replacement in patients with ESLD and ESRD, though current outcomes data are limited. We compared 309 patients (N=29 ESLD and/or ESRD, N=280 control) age 18 who underwent transfemoral TAVR from 2014 to 2020 have been compared. Patients wit
Like
Comment
Share
